**Figure 4. Efficacy study of I-BET151 in xenograft mouse model of MLL-fusion leukaemia.** Female NOD-SCID mice were xenotransplanted with 1x10⁷ MV4;11 cells after conditioning with Busulfan. Following establishment of disease (detectable MV4;11 cells from retro-orbital bleeds), mice were randomly assigned to receive daily IP injections of 20 mg/kg I-BET151 or vehicle control. (**A**) Kaplan-Meier plot of survival during the course of the study. Green arrowhead indicates when treatment commenced on day 40 with treatment continuing for the pre-specified period of 21 days. Animals with no detectable disease at the time of sacrifice (less than 0.5% of MV4;11 cells) or that were unable to be evaluated at the time of death were censored (denoted by a cross). Number of mice monitored: n=11 for vehicle group and n=12 for I-BET151 group. Log-rank (Mantel-Cox) test of I-BET151 treatment compared to vehicle control (_p_ = .536). Access the [analysis script][1] for the statistical tests related to this figure. The script will call the [data][2] directly from the OSF. ------------- All mice had detectable leukaemia at time of randomization and variability of disease burden was evenly distributed among the two conditions (Student’s _t_-test; _t_(21) = 0.028, _p_ = .978). Access the [analysis script][3] for the statistical tests related to this test. The script will call the [data][4] directly from the OSF. [1]: https://osf.io/fcg62/ [2]: https://osf.io/zty4c/ [3]: https://osf.io/5h42u/ [4]: https://osf.io/wgah4/